0
0
9/21/23 at 6:02am
Organization
ScienceAlert
Author
Rebecca Dyer
35 words
0
Comments
Lecanemab received FDA approval in January after a phase 3 trial showed it slows cognitive decline in early-stage Alzheimer's patients.
You are the first to view
https://www.sciencealert.com/this-fda-approved-drug-slows-down-alzheimers-we-finally-know-why
Create an account
or login to join the discussion